| Previous Close | 0.9095 |
| Open | 0.9477 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.8700 - 0.9477 |
| 52 Week Range | 0.2800 - 7.4700 |
| Volume | 43,289 |
| Avg. Volume | 597,062 |
| Market Cap | 27.501M |
| Beta (5Y Monthly) | -0.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NEWTOWN, Pa., Feb. 24, 2020 -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”) CEO Philippe Deschamps has been invited to brief the US.
The Cline Medical Centre in Nanaimo is the Eighth Authorized PoNS Treatment™ Clinic in Canada. Cline Medical Centre is a leading integrative and functional medicine healthcare facility located at 2090 Skaha Drive, Nanaimo, BC.
A live webcast of the call will also be provided on the Events section of the Company's investor relations website at https://78449.themediaframe.com/dataconf/productusers/hls/mediaframe/35777/indexl.html. For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13698861. The webcast will be archived on the Events section of the Company’s investor relations website.
KITE is the research arm of the Toronto Rehabilitation Institute and one of the principle research enterprises at the University Health Network (UHN), Canada’s largest medical research hospital. KITE is a world leader in the field of complex rehabilitation research, with scientists and staff dedicated to improving the lives of people living with the effects of disability, illness and aging.
NEWTOWN, Pa., Jan. 16, 2020 -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness,.
This prestigious award, presented by the Brain Mapping Foundation (BMF) and Society for Brain Mapping and Therapeutics (SBMT), is given to trailblazing technology companies and their CEOs/Presidents who have facilitated the development of pioneering technologies through interdisciplinary approaches that have impacted diagnostics, treatment, and healthcare delivery in unprecedented ways.
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (the “Company”), a neurotech company focused on neurological wellness, announced today that the results from independent research conducted at the University of Wisconsin-Madison on translingual neurostimulation for the treatment of chronic symptoms due to mild-to moderate traumatic brain injury (“mmTBI”) have been published in the December 2019 issue of the Archives of Rehabilitation Research and Clinical Translation. The newly published results from the double-blind randomized clinical trial which paired translingual neurostimulation using the Portable Neuromodulation Stimulator (PoNS™) device with therapeutic activities, showed significantly improved balance and gait scores over the 14-week treatment period and the outcomes were sustained for 12 weeks after discontinuing the treatment.
The gross proceeds to Helius from this offering are expected to be approximately $1.7 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the securities in the offering will be sold by Helius. The offering is expected to close on or about November 26, 2019, subject to customary closing conditions including the approval of the Toronto Stock Exchange.
All of the securities in the offering will be sold by Helius. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
P3 Health is a leading healthcare facility located in downtown Toronto’s St. Lawrence Market area at 145 Front Street East Suite G2 Toronto, Ontario Canada M5A 1E3. Since the opening of the first certified clinic, Neurotherapy Montreal, in December 2018, the Company has made it a priority to make the PoNS accessible to Canadians from coast-to-coast.
NEWTOWN, Pa., Nov. 12, 2019 -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness,.
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today is providing an update outlining the Company’s US regulatory strategy following its pre-submission meeting with the U.S. Food and Drug Administration (“FDA”). Mr. Deschamps continued, “We thank FDA for their feedback on our plans during the recent pre-submission meeting and look forward to further collaboration with the Agency as we prepare our new de novo submission.
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that third quarter of fiscal year 2019 financial results will be released before the market opens on Tuesday, November 12th. A live webcast of the call will also be provided on the Events section of the Company's investor relations website at https://event.on24.com/wcc/r/2079936/B1A21ECCA04BFBE67C9C9E27C2869A30. The webcast will be archived on the Events section of the Company’s investor relations website.
Helius Medical Technologies, Inc. and HealthTech Connex, leading providers of innovative neurological health solutions, announce the grand opening of Apollo Physical Therapy Centre (“Apollo”), Canada’s fifth clinic to offer the groundbreaking PoNS Treatment™ featuring the non-invasive PoNS™ (Portable Neuromodulation Stimulator) device.
Company lineup is filling up fast with 50 good names in the microcap markets, as well as some great private and Pre-IPO companies AUSTIN, TX / ACCESSWIRE / September 19, 2019 / The MicroCap Rodeo's inaugural ...
NEWTOWN, Pa., Sept. 13, 2019 -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness,.
LOS ANGELES, CA / ACCESSWIRE / September 9, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ:HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between November 9, 2017 and April 10, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 9, 2019.
NEW YORK, NY / ACCESSWIRE / September 9, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ:HSDT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Helius securities from November 9, 2017 and April 10, 2019, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ: HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
NEW YORK, NY / ACCESSWIRE / September 8, 2019 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Helius Medical Technologies, Inc. (NASDAQ:HSDT) from November ...
LOS ANGELES, CA / ACCESSWIRE / September 7, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ:HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between November 9, 2017 and April 10, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 9, 2019.
NEW YORK, NY / ACCESSWIRE / September 6, 2019 / Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Helius Medical Technologies, Inc. (NASDAQ:HSDT) ...
LOS ANGELES, CA / ACCESSWIRE / September 6, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ:HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between November 9, 2017 and April 10, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 9, 2019.
Pomerantz LLP announces that a class action lawsuit has been filed against Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ: HSDT) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and indexed under 19-cv-07171, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise Helius securities between November 9, 2017, and April 10, 2019, inclusive (the “Class Period”), seeking to pursue remedies under the Securities Exchange Act of 1934 (the “Exchange Act”). If you are a shareholder who purchased Helius securities during the class period, you have until September 9, 2019, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980.